The FDA Peptide Panel's Industry-Tie Controversy: Who Actually Decided the BPC-157 Vote?

What Did New Reporting Reveal About the PCAC Panel?

The FDA's 23-24 July vote recommending six of seven peptides for pharmacy compounding, including BPC-157, TB-500 and KPV, was already controversial for overriding the agency's own scientific staff. In late June and early July 2026, a separate line of reporting added a second layer to that controversy: who was actually sitting on the Pharmacy Compounding Advisory Committee (PCAC) when it voted.

The Associated Press reported that most of eight new temporary voting members added to PCAC ahead of the hearing had financial or professional ties to clinics and businesses that sell or promote peptides. The story was carried by NBC News, Healio, Becker's Hospital Review and dozens of other outlets in the days before and after the vote.[1] Bloomberg Law separately reported that the FDA moved to add further temporary voting members with academic and clinical-research backgrounds in the weeks before the hearing, a step several outlets characterised as a response to the mounting criticism.[2]

Who Were the Named Appointees With Industry Ties?

AP's reporting named these three individuals specifically, while describing the broader pattern across the eight-person bloc as one where all but one appointee had some identifiable financial or clinical-practice connection to the peptide trade.[1] None of this reporting alleges that any individual broke FDA disclosure rules; advisory-committee members can serve with a granted conflict-of-interest waiver, and the public record reviewed by these outlets did not resolve whether waivers were sought or issued for each appointee.

Did This Bloc Decide the BPC-157, TB-500 and KPV Vote?

On 23 July, the committee voted 8-6, with one abstention, to recommend BPC-157, TB-500 and KPV together for the Section 503A Bulk Drug Substances list — the vote detailed in our PCAC vote outcome guide. NBC News's reporting noted that the eight newly added temporary voting members voted yes as a group on the Day 1 compounds.[1]

That is a statement about vote arithmetic, not a legal finding of impropriety. PCAC's recommendation stands as issued regardless of who cast the votes; nothing in US administrative law automatically invalidates an advisory-committee vote because of a composition dispute reported after the fact.

How Did the FDA Respond to the Criticism?

Per Bloomberg Law, the agency added further temporary voting members with backgrounds in clinical research, academic medicine and pain management to the committee roster in the run-up to the hearing.[2] That step diluted the proportion of appointees with direct peptide-industry ties among the full voting pool, though it did not remove the original eight or retroactively alter the Day 1 vote.

Separately, and more substantively for the underlying science: FDA's own reviewers had already posted a briefing document on 29 June 2026 — before any of this composition reporting broke — concluding there was no identified human-administration data for TB-500 or KPV and insufficient evidence to evaluate BPC-157 for its proposed uses. We covered that document in detail in our FDA evidence-review guide. The committee's eventual vote did not follow its own agency's scientific staff, a fact that predates and is independent of the panel-composition story.

Does the Controversy Change What the Vote Legally Means?

No. A PCAC recommendation is advisory only, regardless of who sat on the panel or how they were appointed. The FDA still has to independently decide whether to open a formal notice-and-comment rulemaking process before BPC-157, TB-500 or KPV could actually be added to the Section 503A list — the same advisory-only status every one of our PCAC guides has flagged since before the hearing took place.

The composition story does, however, sharpen a point worth separating clearly: an advisory-committee recommendation subject to this kind of appointment dispute is a different category of evidence entirely from a licensed pharmaceutical company's Phase 3 programme. Retatrutide's ongoing FDA review, for instance, rests on placebo-controlled trial data from thousands of participants across five completed Phase 3 or Phase 3-equivalent studies, not a single committee vote — see our TRIUMPH-2 & TRIUMPH-3 results guide for that data set. Treating a contested advisory vote and a completed clinical trial programme as equivalent forms of evidence is exactly the kind of conflation researchers should avoid.

What Should UK Researchers Take From This?

Nothing about this story changes the regulatory status of BPC-157, TB-500 or KPV as research reagents in the UK. The Section 503A Bulk Drug Substances List and the PCAC advisory process are US-specific mechanisms governing whether US-licensed compounding pharmacies may prepare these peptides for prescription dispensing; they have no legal force here, where supply is governed separately by the Human Medicines Regulations 2012 and MHRA guidance. See our guide on whether research peptides are legal in the UK for the fuller picture.

If anything, a controversy over who was voting and why reinforces the underlying caution both FDA staff and patient-safety groups have raised throughout this process: the published human evidence base for several of these compounds remains thin. That is precisely why Velox Peptides supplies BPC-157, TB-500 and KPV strictly as HPLC-verified in vitro research reagents, with batch-specific certificates of analysis, and makes no therapeutic or health claims for any of them.

These compounds are supplied as research reagents only. None are medicines and none have been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions